Neurogene Inc. (NGNE) has disclosed a new risk, in the Corporate Activity and Growth category.Don't Miss out on Research Tools:Discover the ...
Neurogene has a $903M market cap with two phase 1/2 assets, NGN-401 for Rett Syndrome and NGN-101 for CLN5 Batten Disease.
Neurogene (NGNE) announced an update on its ongoing Phase 1/2 open-label clinical trial evaluating NGN-401 gene therapy for the treatment of ...
Monday closed up +0.39%, the Dow Jones Industrials Index ($DOWI) (DIA) closed down -0.13%, and the Nasdaq 100 Index ($IUXX) ...
Neurogene reports interim Phase 1/2 trial results for NGN-401 gene therapy in treating pediatric Rett syndrome, showing ...
Neurogene (NASDAQ:NGNE) shares plunged 36% Monday after the company issued an update on a Phase 1/2 study of its gene therapy ...
Neurogene (NGNE, Financials) shares fell 35% in Tuesday's pre-market trading following the release of interim results from a phase 1/2 trial for NGN-401, its gene therapy candidate targeting Rett ...
BMO Capital lowered the firm’s price target on Neurogene (NGNE) to $60 from $65 and keeps an Outperform rating on the shares. The company’s Phase 1/2 readout was a validation of NGN-401 in ...
Stifel raised the firm’s price target on Neurogene (NGNE) to $60 from $44 and keeps a Buy rating on the shares. The firm believes preliminary NGN-401 Phase 1/2 data “transcend the signal-to ...
Neurogene Gene Therapy Shows Signs of Efficacy in Small Study, But an Adverse Event Spooks Investors
A Neurogene gene therapy in development for the rare neurodevelopmental disorder Rett syndrome has encouraging early data in a small group of patients, an interim readout that comes a week after a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback